T1	Participants 137 161	metastatic breast cancer
T2	Participants 868 995	Despite over-accrual of 475 patients, the trial matured with only 324 of 385 planned TtP events due to patient discontinuations
#1	AnnotatorNotes T2	patients had metastatic breast cancer
